Clinical trials: Lung Cancer Patient
Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
This partially randomized phase I/II trial studies the side effects and best dose of sunitinib malate and to see how well it works when given together with cisplatin or carboplatin and etoposide in treating patients with…
- Trial name
- NCT00453154
- Testing
- Carboplatin, Cisplatin, Etoposide
- Where
- 125 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
Successful treatment of lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in the patient's body and seek to limit any unnecessary radiation to normal parts of the body.
- Trial name
- NCT02492867
- Testing
- Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
The purpose of this study is to compare the frequency and abundance of T790M mutation among the different Clinical modes of EGFR-TKI failure.
- Trial name
- NCT02418234
- Testing
- mutation detection, ARMS and ddPCR, ctDNA analysis
- Where
- China
- Volunteers
- 314 people
- Sponsor
- First People's Hospital of Hangzhou
Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell…
- Trial name
- NCT01342965
- Testing
- Erlotinib, Chemotherapy
- Where
- 28 sites in China, Malaysia and 1 more
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer, Non-small Cell Lung Cancer
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Primary Objectives: To characterize the safety and tolerability of isatuximab in combination with REGN2810 in participants with metastatic, castration-resistant prostate cancer (mCRPC) who were naïve to anti-programmed cell…
- Trial name
- NCT03367819
- Testing
- Isatuximab SAR650984, Cemiplimab REGN2810
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Sanofi
Breast Cancer, Prostate Cancer
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
This was a Phase II, multi-center, open label, single dose study in patients with tumor types known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate, colorectal, Non-Small Cell Lung Cancer…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, Non Small Cell Lung Cancer
- Trial name
- NeoFIND (NCT03724253)
- Testing
- [68Ga]-NeoBOMB1
- Where
- 3 sites in Austria, France
- Volunteers
- 19 people
- Sponsor
- Advanced Accelerator Applications
Non-Small Cell Lung Cancer
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
The main objective of this study was to evaluate the anti-tumor activity of gimistotug (BGB-A445) plus investigational agents in participants with non-small cell lung cancer (NSCLC).
- Trial name
- NCT06029127
- Testing
- Gimistotug, Docetaxel, BGB-15025
- Where
- 18 sites in China, South Korea
- Volunteers
- 35 people
- Sponsor
- BeiGene
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.
- Trial name
- PACIFIC (NCT02125461)
- Testing
- MEDI4736
- Where
- 236 sites in United States, Australia and 24 more
- Volunteers
- 713 people
- Sponsor
- AstraZeneca
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Small Cell Lung Cancer, Lung Cancer
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer
Pazopanib is a drug that inhibits proteins thought to be important for new blood vessel formation. This drug has been used in other cancer research studies and information from those studies suggests that pazopanib may help block…
- Conditions
- Small Cell Lung Cancer, Lung Cancer, SCLC
- Trial name
- NCT01253369
- Testing
- Pazopanib
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Dana-Farber Cancer Institute
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
This randomized phase II trial studies how well giving topotecan hydrochloride or cyclodextrin-based polymer-camptothecin CRLX101 works in treating patients with recurrent small cell lung cancer.
- Trial name
- NCT01803269
- Testing
- topotecan hydrochloride, cyclodextrin-based polymer-camptothecin CRLX101
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Chicago
Non-Small Cell Lung Cancer
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
This is a single-arm, open-label, multicenter, international pilot study to evaluate changes that occur in 2-deoxy-2-[18F]fluoro-D-glucose (FDG)- and 3'-deoxy-3'-[18F]fluorothymidine(FLT)-PET (Positron Emission Tomography)…
- Trial name
- NCT00453362
- Testing
- 2-deoxy-2-[18F]fluoro-D-glucose (FDG), 3'-deoxy-3'-[18F]fluorothymidine (FLT), erlotinib HCl
- Volunteers
- 88 people
- Sponsor
- Genentech, Inc.
Urothelial Carcinoma, Urothelial Cancer
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
Background: EP0057 (formerly CRLX101) consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or "nanoparticle drug conjugate" travels through the blood.
- Conditions
- Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer
- Trial name
- NCT02769962
- Testing
- EP0057, olaparib, CT scan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer With Bone Metastatses
BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
In this study patient's will receive the medicine Xofigo which is a radioactive drug that is FDA approved to treat prostate cancer that has spread to the bones.
- Trial name
- NCT02283749
- Testing
- Xofigo
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Angela Taber MD
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- BIRCH (NCT02031458)
- Testing
- Atezolizumab
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 667 people
- Sponsor
- Hoffmann-La Roche
Metastatic Non-Small Cell Lung Cancer, NSCLC
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in…
- Conditions
- Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer
- Trial name
- PRESERVE 4 (NCT04863248)
- Testing
- Trilaciclib, Docetaxel
- Where
- 12 sites in United States
- Volunteers
- 10 people
- Sponsor
- G1 Therapeutics, Inc.
Carcinoma, Non-Small-Cell Lung
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer
This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based expression profile to determine chemotherapy sensitivity in completely resected early stage non-squamous…
- Trial name
- TOP0703 (NCT00545948)
- Testing
- Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Non-small Cell Lung Cancer
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
This is an open-label, non-randomized, phase II clinical research study designed to assess the safety and efficacy of nivolumab and ipilimumab in combination with paclitaxel in patients with treatment naïve NSCLC.
- Trial name
- TOP1705 (NCT03573947)
- Testing
- Nivolumab, Ipilimumab, Paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Jeffrey Clarke
Non-Small-Cell Lung Carcinoma
A Study in Non-Small Cell Lung Cancer
The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced…
- Trial name
- NCT01232452
- Testing
- Pemetrexed, Cisplatin, Cixutumumab
- Where
- 44 sites in United States, Argentina and 10 more
- Volunteers
- 172 people
- Sponsor
- Eli Lilly and Company
Previously Treated Non Small Cell Lung Cancer
A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 plus antimitotic agent and Placebo plus an antimitotic agent in Previously Treated Non-Small-Cell Lung Cancer Patients
- Trial name
- NCT02087176
- Testing
- AZD1775, Antimitotic Agent, pegfiligrastim
- Where
- 12 sites in United States
- Volunteers
- 48 people
- Sponsor
- AstraZeneca